Form 4: FibroBiologics Director Stacy Ann Coen Acquires Stock Options
SEC Form 4 Filing
Director Stacy Ann Coen acquired 5,000 stock options in FibroBiologics, Inc. on August 27, 2024, at an exercise price of $1.73.
Summary
- On August 27, 2024, Stacy Ann Coen, a director of FibroBiologics, Inc. (FBLG), acquired 5,000 stock options.
- The options have an exercise price of $1.73.
- The options vest in full upon the earlier of the first anniversary of the grant date or the date of the next annual meeting.
- The options expire on August 26, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The acquisition of options by a director is mildly positive, suggesting confidence, but not definitively so.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/27/2024 | Date of transaction: Stacy Ann Coen acquired stock options. |
| 08/26/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.